SARS-CoV-2感染中的静脉血栓栓塞:流行病学、病理生理与抗凝治疗及试验
本综述评估了SARS-CoV-2感染相关凝血病的机制及抗凝治疗作用。文献回顾显示危重患者VTE发生率为21%至69%,突破性VTE可在充分预防或治疗剂量抗凝下发生。病理生理涉及细胞介导炎症、内皮炎、细胞因子释放综合征和纤溶失调。肝素可同时针对病毒感染、炎症和血栓形成。所有住院患者应早期VTE预防,危重患者治疗性抗凝可能有益,目前有39项正在进行试验。
要点
- 危重SARS-CoV-2感染患者VTE报告发生率为21%至69%。
- 突破性VTE指充分化学预防或治疗剂量抗凝下仍发生急性VTE。
- 所有住院患者应接受早期VTE预防,危重患者可考虑治疗性抗凝。
核心结论
- SARS-CoV-2感染过度的炎症反应可导致高凝状态、微血栓形成、大血管血栓形成甚至死亡。
- 炎症与血栓形成的相互作用是SARS-CoV-2病毒感染标志性特征。
研究设计与样本
- 本文为文献综述,检索了COVID-19/SARS-CoV-2与细胞介导炎症、临床凝血异常、高凝状态、肺血管内凝血病及抗凝相关文献。
- 同时查询了National Clinical Trials数据库以了解正在进行的抗凝和/或抗血栓治疗研究或血栓事件发生率/患病率研究。
主要发现
- 危重SARS-CoV-2感染患者VTE报告发生率为21%至69%。
- 突破性VTE可在充分化学预防或治疗剂量抗凝下发生,并与严重感染相关。
- 随着感染恶化,可出现极度D-二聚体升高、显著血小板减少、纤维蛋白原下降及凝血酶原时间和部分凝血活酶时间延长,常与深静脉血栓、原位肺血栓和/或肺栓塞相关。
- 肺血管内凝血病这一新现象与重症患者病残率相关。
关键数值与推荐
- 所有住院患者应接受早期VTE预防。
- 治疗性抗凝可能对危重患者有益,是目前39项正在进行试验的焦点。
- 应密切监测血栓并发症,一旦确诊应早期从预防性抗凝转为治疗性抗凝。
临床怎么用
- 对所有住院SARS-CoV-2感染患者提供早期VTE预防。
- 对危重患者考虑治疗性抗凝的可能性,并密切监测血栓并发症。
- 确诊血栓并发症后应早期从预防性抗凝转为治疗性抗凝。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus confers a risk of significant coagulopathy, with the resulting development of venous thromboembolism (VTE), potentially contributing to the morbidity and mortality. The purpose of the present review was to evaluate the potential mechanisms that contribute to this increased risk of coagulopathy and the role of anticoagulants in treatment. METHODS: A literature review of coronavirus disease 2019 (COVID-19) and/or SARS-CoV-2 and cell-mediated inflammation, clinical coagulation abnormalities, hypercoagulability, pulmonary intravascular coagulopathy, and anticoagulation was performed. The National Clinical Trials database was queried for ongoing studies of anticoagulation and/or antithrombotic treatment or the incidence or prevalence of thrombotic events in patients with SARS-CoV-2 infection. RESULTS: The reported rate of VTE among critically ill patients infected with SARS-CoV-2 has been 21% to 69%. The phenomenon of breakthrough VTE, or the acute development of VTE despite adequate chemoprophylaxis or treatment dose anticoagulation, has been shown to occur with severe infection. The pathophysiology of overt hypercoagulability and the development of VTE is likely multifactorial, with evidence supporting the role of significant cell-mediated responses, including neutrophils and monocytes/macrophages, endothelialitis, cytokine release syndrome, and dysregulation of fibrinolysis. Collectively, this inflammatory process contributes to the severe pulmonary pathology experienced by patients with COVID-19. As the infection worsens, extreme D-dimer elevations, significant thrombocytopenia, decreasing fibrinogen, and prolongation of prothrombin time and partial thromboplastin time occur, often associated with deep vein thrombosis, in situ pulmonary thrombi, and/or pulmonary embolism. A new phenomenon, termed pulmonary intravascular coagulopathy, has been associated with morbidity in patients with severe infection. Heparin, both unfractionated heparin and low-molecular-weight heparin, have emerged as agents that can address the viral infection, inflammation, and thrombosis in this syndrome. CONCLUSIONS: The overwhelming inflammatory response in patients with SARS-CoV-2 infection can lead to a hypercoagulable state, microthrombosis, large vessel thrombosis, and, ultimately, death. Early VTE prophylaxis should be provided to all admitted patients. Therapeutic anticoagulation therapy might be beneficial for critically ill patients and is the focus of 39 ongoing trials. Close monitoring for thrombotic complications is imperative, and, if confirmed, early transition from prophylactic to therapeutic anticoagulation should be instituted. The interplay between inflammation and thrombosis has been shown to be a hallmark of the SARS-CoV-2 viral infection.
引用
- Obi AT, Barnes GD, Napolitano LM, et al. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32916371. doi:10.1016/j.jvsv.2020.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。